Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G earnings

This article was originally published in The Tan Sheet

Executive Summary

Volume for Prilosec OTC (omeprazole magnesium) in the first quarter of 2006 more than doubled over the prior-year period, "driven largely by customer pre-buying ahead of the 10% price increase in mid-September and a base period suppressed by shipments allocation," the Cincinnati-based firm states during its first-quarter earnings call Nov. 1. The heartburn treatment continues to garner U.S. value share, which has grown by more than five points since 2005 to 36%, Treasurer John Goodwin stated. In oral care, Crest Pro-Health rinse has earned a 10% share of the mouthwash segment in the six months since its debut, Goodwin added. Overall, the healthcare business unit had "very strong top and bottom line results" during the quarter (ended Sept. 30), with sales increasing 13% to $2.1 bil. Net income grew 37% to $336 mil...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS098808

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel